Jagsonpal Pharma Q1 FY27: Revenue up 9%, PAT up 22%, Cash ₹1,700 Mn
Jagsonpal Pharmaceuticals announced its Q1 FY27 results, reporting a strong start to the fiscal year. Revenue increased by 9% year-on-year to ₹822 Mn, while Profit After Tax (PAT) saw a significant jump of 22% to ₹132 Mn. Operating EBITDA also grew by 21% YoY to ₹191 Mn, with margins expanding by 241 bps to 23.2%. The company maintained robust liquidity with cash reserves of ₹1,700 Mn, even after a ₹400 Mn share buyback. The acquisition of Aequitas Healthcare was completed, marking the company's entry into the hospital business segment, with a target of ₹100+ Mn EBITDA from Aequitas within two years post-integration. The company's market share improved, ranking #88 in the Indian pharmaceutical market.
Key Highlights
- Revenue grew 9% YoY to ₹822 Mn; PAT up 22% YoY to ₹132 Mn.
- Operating EBITDA rose 21% YoY to ₹191 Mn, with margins expanding.
- Cash reserves remain strong at ₹1,700 Mn post buyback and acquisition.
- Acquisition of Aequitas Healthcare completed, entering hospital business.
- Market rank improved to #88 in the Indian pharmaceutical market.
Price Impact
More from JAGSNPHARM